Study links HRT use in midlife to lower dementia risk
New research on 183,000 UK women suggests starting HRT between 46 and 56 may cut dementia risk, with greatest benefits for certain groups.
The Full Story
A plain summary built from the channels that reported this story.
A large UK study has found that starting hormone replacement therapy (HRT) between the ages of 46 and 56 may be associated with a lower risk of dementia later in life. The research, which analysed data from more than 183,000 postmenopausal women, found that those who took HRT had a 10% reduced risk of all dementia and a 16% reduced risk of Alzheimer's disease specifically.
The findings come from a team led by Professor Anne-Marie Minnehane at the Norwich Institute of Healthy Aging. Over a 13-year follow-up period, almost 4,000 women in the study were diagnosed with dementia. The strongest benefits were seen among women who started treatment in their late 40s to mid-50s, a window that appears to matter for cognitive health.
Professor Minnehane said the results add much-needed clarity to a topic with mixed evidence. She noted that certain groups seemed to benefit more than others, including women who had undergone surgical menopause, those with a shorter lifetime exposure to estrogen, and carriers of the APOE4 gene, which is a known risk factor for Alzheimer's disease.
The timing of HRT appears to be important. "It seems to be if there's a short gap between women's natural decline in estrogen and when you start HRT, that's when the benefits are most evident," she said. She explained that brain areas crucial for memory and thinking are rich in estrogen receptors, and that estrogen helps with glucose use, blood flow, and controlling inflammation in the brain.
However, the professor stressed that HRT is not suitable for everyone. Women with a history of strokes, blood clots, or estrogen-sensitive cancers should discuss the risks with their clinician. "The choice to take HRT is a very personal one and should always come down to the wishes of the woman, her health status, and a conversation with the clinicians," she said.
The study adds to a growing body of evidence on HRT and dementia, but it is observational, meaning it cannot prove cause and effect. Still, the scale of the data and the specific age window identified offer practical guidance for women and doctors navigating menopause treatment decisions.
On screen
Stills are sampled automatically at 60-second intervals. Where shown, the still is the nearest available frame from the relevant broadcast segment and is included to show what was on screen during that part of the broadcast. A still may not correspond to the exact second of a quoted phrase.
Key Claims
Claims reported during this story's coverage, mapped by channel. Ordered by how many channels carried each claim.
| Claim | ITV |
|---|---|
| A study analysed data from over 183,000 postmenopausal women in the UK. | |
| HRT use was reported to reduce the risk of all dementia by 10% and Alzheimer's disease by 16%. | |
| The greatest benefit from HRT was reported for women who started between ages 46 and 56. |
Channel Perspectives
What each channel focused on, with key quotes.
ITV1 presented the study as a significant development, framing it around a 'window of opportunity' for women. The channel gave substantial airtime to an interview with the lead researcher, highlighting her excitement and the biological plausibility behind the findings, while also balancing with cautions about who should not take HRT.
- “Yeah, we are quite excited. Good afternoon, everyone.”
- “It seems to be if there's a short gap between women's natural decline in estrogen and when you start HRT That's when the benefits are most evident”
- “The choice to take all HRT is a very personal one and should always come down to the wishes Of the woman, you know her health status And and and a conversation with the clinicians”
Broadcast Timeline
News broadcasts tracked for this story, in time order.